Arbor Pharmaceuticals

38 articles about Arbor Pharmaceuticals

• 

  Global Roundup: Celltrion Prepares to Trap COVID-19 in Phase III

  2/10/2022

  Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.

• Azurity Pharmaceuticals to Acquire and Merge with Arbor Pharmaceuticals

  8/24/2021

  Azurity Pharmaceuticals, Inc. (“Azurity”) and Arbor Pharmaceuticals, Inc. (“Arbor”) today announced they have entered into a definitive agreement in which Azurity will be acquiring Arbor from existing investors including JW Asset Management and KKR.

• Arbor Presents Data from Pivotal Study of AR19, an Investigational ADHD Prescription Stimulant Treatment Specifically Designed to Resist Physical Manipulation for Nonmedical Misuse or Abuse

  9/10/2020

  Arbor Pharmaceuticals, LLC, a U.S.-based specialty pharmaceutical company, announced today the presentation of positive safety and efficacy results from the pivotal Phase 3 study in adults of AR19, its investigational immediate-release, amphetamine sulfate capsule for the treatment of attention-deficit/hyperactivity disorder (ADHD

• Arbor Pharmaceuticals, LLC Confirms Availability of Triptodur® (triptorelin) for Patients with Central Precocious Puberty

  8/25/2020

   Arbor Pharmaceuticals, LLC, a U.S.-based specialty pharmaceutical company, today affirmed the full availability of Triptodur ® (triptorelin), a twice yearly injectable gonadotropin releasing hormone agonist (GnRHa) for the treatment of pediatric

• Arbor Pharmaceuticals Announces FDA Filing Acceptance of New Drug Application (NDA) for AR19, an Investigational ADHD Prescription Stimulant Treatment Specifically Designed to Resist Physical Manipulation for Nonmedical Misuse or Abuse

  5/13/2020

  If approved, AR19 would be the first-ever FDA-approved ADHD stimulant medication designed to resist manipulation for nonmedical use, which may help to deter misuse and abuse by intranasal, intravenous and smoking routes of administration   [13-May-2020]   ATLANTA , May 13, 2020 /PRNewswire/ -- Arbor Pharmaceuticals, LLC, a U.S.-based specialty pharmaceutical company, anno

• Arbor Pharmaceuticals Teams Up with Shaquille O'Neal to Help African Americans 'Get Real' About Heart Failure

  3/14/2019

  Partnership to raise awareness of the increased burden of heart failure in African Americans and shed light on approaches to managing the unique challenges facing this patient community

• 

  Edge Craters Following Phase III Failure of Brain-Bleed Drug, Prepares to Cut Staff

  3/29/2018

  Shares of Edge Therapeutics were in free fall Wednesday afternoon following the company’s decision to discontinue development of a late stage treatment for adults with aneurysmal subarachnoid hemorrhage (aSAH).

• Arbor Pharma And Debiopharm Announce Commercial Availability Of Triptodur, Triptorelin 6-Month Formulation, For Treatment Of Central Precocious Puberty (CPP)

  10/3/2017

• Arbor Pharma Launches New Nymalize (Nimodipine) Oral Solution 10 Ml (30 Mg) Unit Dose For The Treatment Of Subarachnoid Hemorrhage

  9/20/2017

• Fosun Pharma, Shanghai Pharma Bid for Arbor Pharma, Deal May Fetch $700 Million

  8/11/2017

• Arbor Pharma And Debiopharm Announce U.S. FDA Approval For Triptodur, Triptorelin 6-Month Formulation, In The Treatment Of Central Precocious Puberty (CPP)

  6/30/2017

• When an Old Study Casted Doubt on Drug, Arbor Pharma Turned to Trump Nominee Tom Price for Help

  1/20/2017

• Laboratorios SALVAT S.A. And Arbor Pharma Announce The Launch Of OTOVEL (Ciprofloxacin 0.3 % And Fluocinolone Acetonide 0.025 %) Otic Solution

  8/30/2016

• Arbor Pharma Completes Successful Tender Offer For Shares Of XenoPort

  7/5/2016

• Arbor Pharma And XenoPort Announce The Expiration Of The HSR Act Waiting Period

  6/16/2016

• Arbor Pharma Shells Out $467 Million for Bay Area’s Restless Leg Drug Company XenoPort

  5/24/2016

• Debiopharm International SA And Arbor Pharmaceuticals Announce Their US Commercialization Partnership For Triptorelin In Central Precocious Puberty

  1/11/2016

• Wilshire Confirms First-to-File Patent Challenge Relating To LASTACAFT

  12/12/2014

• KKR To Invest In Arbor Pharmaceuticals

  12/5/2014

• KKR Takes Undisclosed Stake In Arbor Pharmaceuticals As Specialty Funding Heats Up

  12/5/2014